10-Q: Assembly Bio Reports Strong Q3, Extends Cash Runway

Assembly Biosciences reported increased collaboration revenue and positive clinical trial data for its HSV programs, extending its cash runway into late 2027.

Summary

• Net loss for the three months ended September 30, 2025, was $9.2 million, an improvement from $9.6 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $28.2 million, compared to $29.8 million for the same period in 2024.
• Collaboration revenue from a related party (Gilead) increased to $10.8 million for Q3 2025, up from $6.8 million in Q3 2024, and to $29.8 million for the nine months ended September 30, 2025, from $21.2 million in 2024.
• Cash, cash equivalents, and marketable securities totaled $232.6 million as of September 30, 2025.
• The company's cash runway is projected into late 2027, with potential to extend beyond 2028 with future Gilead payments or warrant exercises.
• Interim Phase 1b data for ABI-5366 showed a highly potent antiviral activity with a 94% reduction in HSV-2 shedding rate (p<0.01) and genital lesion rate (p<0.01) compared to placebo at a 350 mg weekly dose.
• ABI-5366 demonstrated a mean half-life of approximately 20 days, supporting once-weekly oral dosing and potential for once-monthly dosing.
• ABI-1179 Phase 1a data showed a favorable safety profile and a half-life of approximately four days, supporting weekly dosing.
• ABI-6250 Phase 1a interim data showed a mean half-life of approximately four days, supporting once-daily oral dosing, with dose-dependent elevations of total serum bile acids (TBAs) indicating NTCP target engagement.
• ABI-4334 Phase 1b topline results indicated mean declines in HBV DNA of 2.9 log10 IU/mL (150mg cohort) and 3.2 log10 IU/mL (400mg cohort) over 28 days.
• Discovery and development transitioned from ABI-7423 to its parent molecule, ABI-7272, for transplant-related herpesviruses, which is currently in regulatory filing-enabling preclinical studies.
• The company raised aggregate gross proceeds of $175.0 million in August 2025 from an underwritten offering and a private placement with Gilead.

Sentiment

Score: 8

Explanation: The company reported strong clinical trial results for its lead HSV candidate, ABI-5366, exceeding efficacy targets, and significantly bolstered its financial position with a $175 million capital raise, extending its cash runway. While still pre-revenue and incurring losses, these developments are highly positive for its long-term prospects and ability to advance its pipeline.

Positives

• Net loss decreased for both the three-month ($9.2 million vs. $9.6 million) and nine-month ($28.2 million vs. $29.8 million) periods ended September 30, 2025, compared to the prior year.
• Collaboration revenue from Gilead Sciences, Inc. significantly increased by 58% to $10.8 million for Q3 2025 and by 41% to $29.8 million for the nine months ended September 30, 2025.
• The company's cash, cash equivalents, and marketable securities increased substantially to $232.6 million as of September 30, 2025, from $111.2 million at December 31, 2024.
• The cash runway is projected into late 2027, with potential to extend beyond 2028, resolving previous substantial doubt about the company's ability to continue as a going concern.
• Positive interim Phase 1b data for ABI-5366 showed a 94% reduction in HSV-2 shedding rate (p<0.01) and genital lesion rate (p<0.01) compared to placebo, exceeding the target of 80%-85% reduction.
• ABI-5366's mean half-life of approximately 20 days supports convenient once-weekly or potentially once-monthly oral dosing.
• ABI-1179 Phase 1a data demonstrated a favorable safety profile and a half-life supporting weekly dosing.
• ABI-6250 Phase 1a interim data showed dose-dependent elevations of total serum bile acids, indicating successful NTCP target engagement.
• ABI-4334 Phase 1b topline results demonstrated potent antiviral activity with significant mean HBV DNA declines of 2.9-3.2 log10 IU/mL.
• Successful capital raise in August 2025 generated $175.0 million in gross proceeds, strengthening the financial position.

Negatives

• The company has incurred continuous operating losses since inception, with an accumulated deficit of $854.1 million as of September 30, 2025.
• Research and development expenses increased by 23% to $16.6 million for Q3 2025 and by 14% to $47.6 million for the nine months ended September 30, 2025, driven by pipeline advancement.
• General and administrative expenses increased by 19% to $5.1 million for Q3 2025 and by 6% to $14.2 million for the nine months ended September 30, 2025.
• Net cash used in operating activities increased to $55.3 million for the nine months ended September 30, 2025, from $50.7 million in the same period of 2024.
• Interest and other income, net, decreased by 17% to $3.7 million for the nine months ended September 30, 2025, compared to $4.5 million in 2024, due to a smaller portfolio balance for most of the period and lower interest rates.
• One Grade 3 adverse event (hypertriglyceridemia) was reported in the ABI-5366 Phase 1b study, although it was considered unrelated to treatment.
• One Grade 2 ALT elevation was observed in the highest single-dose cohort of ABI-6250, accompanied by off-target engagement of other liver transporters.

Risks

• The company has no approved products and its future success is dependent on the successful development and regulatory approval of its product candidates.
• Additional financing will be required to complete product development and fund future operations, and there is no assurance such funding will be available on acceptable terms, if at all.
• Adverse geopolitical and macroeconomic developments could affect the company's ability to access capital.
• The collaboration with Gilead Sciences, Inc. is critical, and its unsuccessfulness or termination could adversely affect the business, including loss of future funding, milestone, or royalty payments.
• Conflicts may arise with Gilead regarding development, commercialization, or intellectual property, potentially delaying or preventing product development.
• The company is heavily dependent on Gilead for further development and commercialization of optioned programs, and transition delays could impact timelines.
• Gilead's significant ownership (approximately 29%) and board representation may allow it to exert substantial influence over the company.
• Gilead could independently develop or collaborate on products that compete with the company's investigational products.
• The company may face difficulties in establishing new collaborations due to Gilead's option rights on all current and future pipeline programs.
• Nonclinical and clinical studies are expensive, time-consuming, and may fail to demonstrate the necessary safety and efficacy for product approval.
• Results from nonclinical or early-stage clinical studies may not be predictive of later-stage clinical outcomes.
• Clinical studies may be delayed by factors such as regulatory agreements, CRO terms, safety issues, manufacturing challenges, participant recruitment, or regulatory holds.
• Reliance on Contract Research Organizations (CROs) for studies reduces control and introduces risks of non-performance or compromised data quality.
• Risks associated with foreign CROs, vendors, and suppliers include geopolitical actions, different regulatory requirements, reduced intellectual property protection, and trade policy changes.
• The ongoing U.S. government shutdown could prevent government agencies (e.g., FDA, CBP) from performing normal business functions, potentially delaying regulatory reviews and clinical study timelines.
• Top-line, preliminary, or interim data may not accurately reflect final study results, leading to potential negative impacts on regulatory approval or commercialization.
• Competitors may develop treatments that render the company's product candidates or technologies obsolete or non-competitive.
• Negative clinical data from competitors using similar mechanisms of action could adversely affect public and clinical perceptions of the company's product candidates.
• The ability to use net operating loss and credit carryforwards may be limited due to past and future ownership changes.
• The company is subject to extensive and costly government regulation, and non-compliance could result in significant penalties, delays, or withdrawal of approvals.
• Regulatory approval processes are lengthy, unpredictable, and subject to FDA discretion and external factors like government funding and staffing levels.
• Exposure to U.S. federal and state anti-kickback, false claims, physician payment transparency, and health information privacy and security laws (e.g., HIPAA, EU GDPR, UK GDPR, CCPA) could lead to criminal sanctions, civil penalties, or reputational harm.
• The company faces product liability claims inherent in drug development and may not be able to obtain sufficient insurance coverage.
• Liability claims associated with the use of hazardous materials and chemicals in research and manufacturing activities.
• Misconduct by employees, contractors, or collaborators could lead to non-compliance with regulatory standards, fraudulent data, or misappropriation of intellectual property.
• The business depends on protecting its intellectual property, and there is a risk that patents may not be obtained, may be too narrow, or may be challenged.
• Enforcement of intellectual property rights can be difficult in certain countries, and litigation costs can be substantial.
• The company may infringe the intellectual property rights of others, leading to delays, increased costs, or inability to commercialize product candidates.
• The cost of maintaining global patent protection is high and requires continuous review and compliance.
• Intellectual property rights may not address all potential threats to competitive advantage.
• The price of the company's common stock has been and may continue to be volatile, leading to potential investment losses.
• The company's amended and restated bylaws designate the Delaware Court of Chancery as the exclusive forum for certain actions, potentially limiting stockholders' ability to choose a favorable judicial forum.

Future Outlook

The company expects to continue incurring substantial losses for the next several years as it advances its product development efforts, with future operating expenses anticipated to increase. The cash runway is projected into late 2027, with potential for extension beyond 2028 through future payments from the Gilead collaboration or warrant exercises. The company plans to move directly into Phase 2 clinical study preparation for ABI-5366's once-weekly treatment regimen, with chronic toxicology studies complete to support longer-term dosing. Interim data for ABI-1179 weekly dosing and ABI-5366 monthly dosing are expected by the end of 2025. Preparations for Phase 2 clinical studies for ABI-6250 are underway, alongside ongoing chronic toxicology studies. Final ABI-4334 Phase 1b data will be presented in November 2025, and ABI-7272 is currently in regulatory filing-enabling preclinical studies.

Management Comments

• Management believes the company currently has sufficient funds to meet its operating requirements beyond one year from the date these unaudited condensed consolidated financial statements are issued.
• The company concluded the conditions which previously raised substantial doubt about its ability to continue as a going concern have been resolved.
• We expect our future operating expenses to increase over the coming years as we continue to advance our candidates.
• Our operating losses are likely to be substantial over the next several years if none of our product candidates are approved or successfully launched.
• Based on our current operating plan, we believe we have sufficient funds to meet our operating requirements into late 2027.
• This cash runway guidance does not include potential future payments to us under our collaboration with Gilead or from potential warrant exercises, which would further extend our cash runway beyond 2028.

Industry Context

The biotechnology industry is highly competitive and rapidly evolving, particularly in the viral disease space. The company's focus on recurrent genital herpes, HDV, HBV, and transplant-related herpesviruses addresses significant unmet medical needs. Current therapies for genital herpes are only partially effective and lack new mechanisms of action for over 25 years, creating an opportunity for the company's HPIs. HDV is the most severe form of hepatitis with limited approved treatments, especially oral options, positioning the company's entry inhibitor as a potential innovation. Similarly, chronic HBV infection lacks curative therapies and new MOAs, highlighting the importance of the company's next-generation CAM targeting cccDNA. Transplant patients face high risks from herpesvirus infections with current antivirals having limitations, indicating a market for broad-spectrum NNPIs.

Comparison to Industry Standards

• ABI-5366's 94% reduction in HSV-2 shedding rate and genital lesion rate significantly exceeds the company's target of 80%-85% reduction, suggesting a potentially superior efficacy profile compared to current nucleoside analog therapies, which often fail to prevent recurrences in a large portion of patients.
• The long half-life of ABI-5366 (~20 days) and ABI-1179 (~4 days) supports once-weekly or once-monthly dosing, offering a substantial improvement in patient convenience over the high pill burden (one to three times daily) of existing nucleoside analog treatments for recurrent genital herpes.
• ABI-6250, an oral small molecule entry inhibitor for HDV, utilizes the same clinically-validated mechanism of action as bulevirtide, an injectable peptide blocker approved only in Europe. An oral option would represent a significant advancement in treatment convenience and accessibility for HDV patients, where no approved treatments exist in the United States.
• ABI-4334, a next-generation capsid assembly modulator for HBV, is designed to disrupt viral replication and prevent the establishment and replenishment of new cccDNA. This approach targets a key aspect of HBV persistence not directly addressed by current nucleos(t)ide analog reverse transcriptase inhibitors (NrtIs), which have very low cure rates and have seen no new mechanisms of action approved in over 25 years.

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings.

Related Party Transactions

• Gilead Sciences, Inc. is considered a related party due to its ownership of the company's common stock (approximately 29% as of September 30, 2025) and board representation.
• Collaboration revenue from Gilead was $10.8 million for the three months ended September 30, 2025, and $29.8 million for the nine months ended September 30, 2025.
• Accounts receivable from collaboration with Gilead was $0.9 million as of September 30, 2025.
• Deferred revenue from Gilead was $44.1 million as of September 30, 2025 ($42.4 million short-term and $1.7 million long-term).
• In July 2025, the company entered into a letter agreement with Gilead for reimbursement of up to $1.5 million for certain nonclinical study activities.
• In August 2025, Gilead participated in a private placement, purchasing 2,295,920 shares of common stock and accompanying Class A and Class B warrants for aggregate gross proceeds of $45.0 million.
• Gilead has opt-in rights to programs, with potential opt-in fees ranging from $45.0 million to $125.0 million per program.
• Gilead will continue to support the collaboration through extension fees of $75.0 million on the third, fifth, and seventh anniversaries of the collaboration.
• Gilead has the right to acquire additional shares in the open market, up to an amount resulting in Gilead owning a total of 35% of the company's outstanding common stock.
• A Registration Statement on Form S-3 was filed in October 2025 to register all shares of common stock and warrants issued to Gilead.

Stakeholder Impact

• Shareholders: Positive impact from extended cash runway and promising clinical data, but dilution from recent capital raise and ongoing operating losses. Potential for long-term value creation if product candidates achieve regulatory approval and commercial success.
• Employees: Continued employment and potential for stock-based compensation vesting tied to clinical milestones.
• Customers (future): Potential for new, improved, and more convenient treatment options for serious viral diseases like recurrent genital herpes, hepatitis delta virus, and hepatitis B virus.
• Suppliers and Contract Research Organizations (CROs): Continued engagement for ongoing research, development, and manufacturing activities.
• Creditors: Improved financial stability and liquidity reduce immediate credit risk, enhancing the company's ability to meet its obligations.

Next Steps

• Move directly into Phase 2 clinical study preparation for ABI-5366's once-weekly treatment regimen.
• Complete the ongoing Phase 1b study of ABI-5366, which includes an ongoing cohort evaluating a monthly oral dosing regimen.
• Complete ongoing chronic toxicology studies for ABI-5366 to support longer-term dosing in Phase 2.
• Report interim data on two cohorts of weekly dosing of ABI-1179 and one cohort of monthly dosing of ABI-5366 by the end of 2025.
• Prepare for Phase 2 clinical studies for ABI-6250.
• Complete ongoing chronic toxicology studies for ABI-6250.
• Present final ABI-4334 Phase 1b data at the American Association for the Study of Liver Disease, The Liver Meeting in November 2025.
• Continue regulatory filing-enabling preclinical studies for ABI-7272 (transplant-related herpesviruses).
• Continue proprietary research to discover and develop novel antivirals to treat serious viral diseases.
• Seek additional funding through strategic relationships, public or private equity or debt financings, grants, or other arrangements.
• The SEC is to review the Registration Statement on Form S-3 filed in October 2025 for Gilead's shares and warrants, once the U.S. government shutdown ends.

Key Dates

Recommendation

The company has demonstrated promising clinical data for ABI-5366, exceeding efficacy targets, and has significantly strengthened its balance sheet with a substantial capital raise, extending its cash runway. The collaboration with Gilead provides strategic backing and potential future funding. However, the company remains pre-revenue with ongoing substantial operating losses and faces significant risks inherent in drug development, including regulatory hurdles, competition, and the uncertainty of future clinical trial success and commercialization. The stock is a 'Hold' for investors who are comfortable with the high-risk, high-reward nature of biotech investments and believe in the long-term potential of its pipeline, especially given the recent positive developments and improved financial stability.

Keywords

Biotechnology, Drug development, Clinical trials, Herpes Simplex Virus, Hepatitis Delta Virus, Hepatitis B Virus, Helicase-primase inhibitors, Capsid assembly modulator, Non-nucleoside polymerase inhibitor, Antiviral therapies, Gilead Sciences, Financial results, Warrants, Capital raise, SEC filing